This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
« Back
Page 1 of 85851

Initial Data From Ongoing Expansion Study Of MGCD265 Show Preliminary Evidence Of Clinical Efficacy In Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients With MET Gene Alterations

By PR Newswire

- The First Three Patients Selected for MET Gene Alterations in MGCD265 Dose Expansion Cohort Show Clear Evidence of Tumor Regression

09:16AM 05/30/15

Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons Between Tumors That Share Histological Features

By PR Newswire

ASCO Presentations Highlight Therapeutic Implications of Similar Genetic Landscape for Brain Metastases in NSCLC, Breast Cancer and Melanoma, as well as Similarities and Differences Between Endometrial, Renal and Ovarian Cancers

08:00AM 05/30/15

Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations And Confirms Tumor Heterogeneity In High-Grade Glioma Samples

By PR Newswire

Paired Tumor Research in Glioma, Breast Cancer and Epithelial Ovarian Carcinoma Guides Clinical Application of Comprehensive Tumor Profiling

08:00AM 05/30/15

Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions In Risk Of Progression Or Death In Patients With Previously-Treated Chronic Lymphocytic Leukemia

By PR Newswire

Phase 3 data (abstract LBA7005) featured in the official press program of the 51st annual meeting of the American Society of Clinical Oncology

07:32AM 05/30/15

Data Show Daratumumab Achieved A Pronounced Overall Response Rate As A Single-Agent With Tolerable Safety Profile In Heavily Pre-Treated Multiple Myeloma Patients

By PR Newswire

Results from the Phase 2 MMY2002 trial (Abstract LBA8512) featured in the official press program of the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)

07:31AM 05/30/15

« Back
Page 1 of 85851

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs